# Totient

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/totient-2

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.totient.bio
- Total disclosed funding: $10M
- Latest round: Seed (Sep 10, 2020)
- Investors on record: 5

## About

Totient Inc. is a biotechnology company focused on advancing the field of personalized medicine through innovative immune profiling and T cell discovery technologies.Founded in 2017 and based in Cambridge, US, Totient Inc. specializes in the development of immune-targeted therapies. The company has engaged in two funding rounds, with the latest being a SEED round in January 2021, raising USD 10.00 mn from investors including Kaitai Capital, Mission BioCapital, Sands Capital Ventures, Tau Ventures, and Viva Biotech (Shanghai) Ltd. The firm remains independently operated with no known subsidiaries or parent companies.Totient Inc. specializes in immune profiling to facilitate the discovery of T cell therapies, focusing on personalized medicine approaches. The company's key offerings include advanced platforms for identifying novel T cell targets, enabling the development of therapies tailored to individual patients' immune systems.Totient Inc. generates revenue through strategic collaborations with biopharmaceutical companies, focusing on immune-targeted therapy development. Revenue is derived from service agreements involving upfront fees, milestone payments tied to development phases, and royalties from successful commercialization of therapies that utilize its proprietary immune profiling technologies.Following the recent funding round on January 5, 2021, Totient Inc. aims to expand its product portfolio, specifically targeting new immune profiling products and launching them within the next 12 to 18 months. The company is also looking to penetrate international markets, particularly in Europe and Asia, by 2023. The funding received will be utilized to enhance research capabilities and accelerate product development to support these growth initiatives.

## Funding rounds

- Seed, Sep 10, 2020, $10M — Kaitai Capital, Sands Capital Alternatives, Mission Biocapital, Viva Biotech Holdings, Tau Ventures

## Investors

- Kaitai Capital (https://capitalatlas.ai/funds/kaitai-capital) — Seed
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Seed
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Seed
- Viva Biotech Holdings — Seed
- Tau Ventures — Seed